{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:45:51Z","timestamp":1782913551055,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Currently, predictive biomarkers for the efficacy of immunotherapy in metastatic gastric cancer (mGC) during the era of immune checkpoint inhibitors are still under evaluation. The aim of this study is to investigate the predictive value of early C-reactive protein (CRP) kinetics on the efficacy of programmed cell death protein-1(PD-1) inhibitors in mGC patients with microsatellite stable (MSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 59 mGC patients with MSS who had been treated with PD-1 inhibitors as first-line therapy at a tertiary hospital. Based on the \u201cCRP-flare response phenomenon,\u201d the patients were classified into three groups: CRP flare-responders, CRP responders, and non-CRP responders. The primary endpoints were overall survival (OS) and progression-free survival (PFS), while the secondary endpoints included objective response rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 59 patients, 21 were classified as CRP flare-responders, 18 as CRP responders, and 20 as non-CRP responders. The objective response rate for CRP flare-responders, CRP responders, and non-CRP responders were 38.1%, 16.7%, and 5.0% (p=0.031), respectively. The median OS of the CRP flare-responders, CRP responders, and non-CRP responders were 25.8 months, 16.3 months, and 11.9 months (p=0.0009), respectively. The median PFS of the CRP flare-responders, CRP responders, and non-CRP responders were 16.6 months, 6.8 months, and 5.1 months (p=0.0002), respectively. Both univariable and multivariable analyses demonstrated that CRP flare-responders had a significantly higher objective response rate and a lower risk of death compared with non-CRP responders (p &amp;lt; 0.05). Moreover, CRP flare-responders showed a significantly lower risk of disease progression compared with both CRP responders and non-CRP responders (p &amp;lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with MSS mGC receiving first-line PD-1 inhibitor therapy, CRP flare response was associated with improved objective response, PFS, and OS. Early CRP kinetics may represent a promising predictive biomarker for immunotherapy efficacy in MSS mGC. Further large-scale prospective studies are warranted to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1802864","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:57:26Z","timestamp":1782910646000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["C-reactive protein flare-response predicts the efficacy of PD-1 inhibitors in metastatic gastric cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Yi-hui","family":"Lei","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, Xiamen Humanity Hospital","place":["Xiamen, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Nursing, Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-fu","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Xiamen Humanity Hospital","place":["Xiamen, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-yue","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine, Xiamen University","place":["Xiamen, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-bin","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Xiamen Humanity Hospital","place":["Xiamen, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1136437","article-title":"PD-1 inhibitors-based second-line therapy for metastatic gastric cancer","volume":"14","author":"Gou","year":"2023","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.101962","article-title":"Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients","volume":"46","author":"Ma","year":"2022","journal-title":"Clinics Res Hepatol Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s499403","article-title":"The benefits and safety of monoclonal antibodies: Implications for cancer immunotherapy","volume":"18","author":"Zhang","year":"2025","journal-title":"J Inflammation Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jnu.70037","article-title":"The effectiveness of death education on death anxiety, depression, and quality of life in patients with advanced cancer: A meta-analysis of randomised controlled trials","volume":"57","author":"Su","year":"2025","journal-title":"J Nurs Scholarship Off Publ Sigma Theta Tau Int Honor Soc Nurs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188775","article-title":"Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer","volume":"1877","author":"Chen","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Sci (New York NY)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","volume":"454","author":"Medzhitov","year":"2008","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/jci80007","article-title":"Immunity, inflammation, and cancer: an eternal fight between good and evil","volume":"125","author":"Shalapour","year":"2015","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1072480","article-title":"Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review","volume":"13","author":"Lei","year":"2023","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001564","article-title":"Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab","volume":"9","author":"Fukuda","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004024","article-title":"C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer","volume":"10","author":"Kl\u00fcmper","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejca.2022.02.022","article-title":"C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma","volume":"167","author":"Kl\u00fcmper","year":"2022","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s432054","article-title":"Early C-reactive protein kinetics predict response to immune checkpoint blockade in unresectable hepatocellular carcinoma","volume":"10","author":"Qin","year":"2023","journal-title":"J Hepatocellular Carcinoma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2549295","article-title":"Neutrophil-to-lymphocyte ratio (NLR) predicts PD-1 inhibitor survival in patients with metastatic gastric cancer","volume":"2021","author":"Gou","year":"2021","journal-title":"J Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1029960","article-title":"Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment","volume":"12","author":"Wan","year":"2022","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1274431","article-title":"Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer","volume":"14","author":"Hou","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10120-018-00922-8","article-title":"Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer","volume":"22","author":"Sasaki","year":"2019","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Japanese Gastric Cancer Assoc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4461","article-title":"Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC)","volume":"11","author":"Tanaka","year":"2022","journal-title":"Cancer Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ags3.12489","article-title":"The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi-institutional cohort study","volume":"5","author":"Sato","year":"2021","journal-title":"Ann Gastroenterological Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110937","article-title":"Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis","volume":"124","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.56434\/j.arch.esp.urol.20247709.148","article-title":"Computed tomography measures of perinephric adipose tissue and C-reactive protein-to-albumin ratio are associated with common prognostic models for nonmetastatic clear cell renal cell carcinoma patients","volume":"77","author":"Liu","year":"2024","journal-title":"Archivos Espanoles Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2025.109559","article-title":"Analyzing the impact of threshold strategies on cancer treatment using non-smooth models","volume":"390","author":"Wu","year":"2025","journal-title":"Math Biosci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1751463","article-title":"Experimental study on synergistic pulses improving the tumor microenvironment and assisting immunotherapy","volume":"17","author":"Dong","year":"2026","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102399","article-title":"In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence","volume":"6","author":"Guo","year":"2025","journal-title":"Cell Rep Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581398","article-title":"PSMD12 promotes hepatocellular carcinoma progression by stabilizing CDK1","volume":"16","author":"Peng","year":"2025","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13886","article-title":"CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes","volume":"30","author":"Ning","year":"2023","journal-title":"J Viral Hepatitis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1016\/j.devcel.2025.07.014","article-title":"Dapk2 dysfunction leads to Mic60 lactylation and mitochondrial metabolic reprogramming, promoting lung cancer EGFR-TKI resistance and metastasis","volume":"60","author":"Zheng","year":"2025","journal-title":"Dev Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1802864\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:57:26Z","timestamp":1782910646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1802864\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1802864"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1802864","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1802864"}}